MOA Platform Heatmaps
Pick a mechanism-of-action family and see every drug against that target across all indications — “all assets against target X.” Each grid is drugs (rows) × indications (columns), with forward catalysts and per-asset detail.
20 curated families · 654 drugs mapped
IO checkpoint inhibitors
ProPD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3 antibodies and bispecifics — the most-mature IO landscape.
Antibody-drug conjugates (ADCs)
ProAntibody-drug conjugates spanning multiple tumor antigens. The dominant emerging modality across solid tumors.
T-cell engagers (CD3 bispecifics)
ProBispecific antibodies engaging T-cells via CD3 to a tumor antigen. The fastest-growing class in oncology after IO and ADCs.
EGFR family inhibitors
ProEGFR TKIs across generations, exon-20 selective, bispecifics, and EGFR ADCs.
CD19-targeted therapies
ProCD19-directed therapies across modalities (CAR-T, T-cell-engaging bispecifics, mAb/ADC) AND across domains — the heme-oncology workhorse (lymphoma/leukemia) now crossing into autoimmune disease (lupus, myasthenia, scleroderma, myositis), where CD19 CAR-T "resets" the B-cell compartment.
GLP-1 / incretin agonists
ProGLP-1 and multi-incretin (GIP, glucagon, amylin) agonists across obesity, type 2 diabetes, MASH, and cardiometabolic — the highest-value cross-indication race in pharma.
HER2 family
ProHER2 mAbs, ADCs, bispecifics, and small-molecule TKIs.
JAK / TYK2 inhibitors
ProJAK pan / JAK1 / JAK1/2 / JAK3 / TYK2 inhibitors — the oral kinase backbone across immunology, dermatology, myeloproliferative neoplasms, and (emerging) CNS.
KRAS family inhibitors
ProKRAS inhibitors spanning G12C, G12D, G12V, pan-RAS, RAS(ON), KRAS vaccines, and KRAS-targeted TCR-T.
BCMA-targeted therapies
ProBCMA-directed therapies across modalities — CAR-T, T-cell-engaging bispecifics, and ADCs — the dominant target in relapsed/refractory multiple myeloma.
CAR-T cell therapy
ProAutologous and allogeneic CAR-T cells across hematologic and solid tumor targets.
PARP / DDR inhibitors
ProPARP inhibitors and broader DNA-damage-response (ATR, WEE1) inhibitors.
Radioligand therapies
ProPSMA / SSTR2 / FAP-targeted radioligand therapies — the fast-emerging precision-oncology modality.
IL-23 axis inhibitors
ProIL-12/23 (p40) and IL-23 (p19) inhibitors — the dominant immunology class for psoriasis, IBD, and emerging.
TL1A inhibitors
ProTL1A antibodies for IBD — the most-crowded emerging mechanism in UC and CD across 6 sponsors.
Claudin 18.2 targeting
ProClaudin 18.2 mAbs, ADCs, bispecifics, and CAR-T across gastric and PDAC.
Lp(a) lowering
ProTherapies lowering lipoprotein(a) — a genetically-set, long-undruggable cardiovascular risk factor — spanning antisense (ASO), siRNA, and oral small-molecule modalities. One of the most-crowded emerging cardiometabolic races: Novartis, Lilly, and Hengrui each field two assets shown here. Scope: active, industry-sponsored trials registered on ClinicalTrials.gov. A fourth modality — in vivo LPA gene editing — is not shown, for different reasons: CRISPR Therapeutics CTX320 (Phase 1) is registered ex-US on ANZCTR (not ClinicalTrials.gov), and Eli Lilly VERVE-301 (from its 2025 Verve acquisition) is still preclinical with no trial registered.
mRNA cancer vaccines
PromRNA/saRNA therapeutic cancer vaccines — personalized-neoantigen, shared-antigen, and self-amplifying. V940 (Merck/Moderna) posted the first positive Phase 3 for an mRNA cancer vaccine — the biggest cancer-vaccine readout since sipuleucel-T (2010): INTerpath-001, adjuvant melanoma, met recurrence-free and distant-metastasis-free survival (announced Aug 2026).
MTAP synthetic-lethal inhibitors
ProPRMT5 and MAT2A inhibitors exploiting MTAP-deletion vulnerability — selective oncology synthetic-lethal class.
S1P modulators
ProSphingosine-1-phosphate receptor modulators for UC, MS, and other indications.
Data: ClinicalTrials.gov · Curated target-family rosters · Updated weekly.